Veriheal

MAY 26, 2022

Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them. RoC also works to increase patients’ access to medical cannabis by helping U.S. To date, Veriheal’s global team has helped hundreds of thousands of patients gain access to medical cannabis.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Cannabis Law Report

MAY 19, 2022

.” Hartle, 54, is one of the very few Canadians to have received legal psychedelics psychotherapy for a mental health condition since Health Canada made it easier in January for health-care workers to access psilocybin — the hallucinogenic compound found in some mushrooms. In April, a clinic called Roots To Thrive, in Nanaimo, B.C.,

Therapy 52

Therapy Patients Treatment Clinical Trials 52

MMJ Recs

DECEMBER 17, 2023

The Texas Compassionate Use Program (TCUP) represents the Lone Star State’s cautious foray into the realm of medical marijuana. Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals.

Law 52

Law Dispensary Clinical Trials Programs 52

Cannabis Law Report

AUGUST 7, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Otherside Farms

JANUARY 25, 2019

A medical marijuana patient in Los Angeles with inoperable liver cancer has been removed from Cedars-Sinai Medical Center’s transplant list after testing positive for marijuana. Sixty-three-year-old medical marijuana patient Norman B. The letter also urges Cedars-Sinai to change its transplant eligibility policy. Dr. Steven D.

Patients 76

Patients Clinical Trials Marijuana Policy 76

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. CBD Oil for Medical Conditions CBD oil has gained popularity as a versatile and accessible option for managing various medical conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Canna Law Blog

NOVEMBER 10, 2020

We discussed how licensed facilities won’t be up and running for a few more years, and how, in the meantime, people will have to make do with general decriminalization under Measure 109 and maybe, in certain cases, reliance on Right to Try access. It’s quite restrictive. Or, it could be because FDA is sort of a drag about everything.

Therapy 78

Therapy Clinical Trials Decriminalization Patients 78

Cannabis Law Report

AUGUST 10, 2022

According to CAMH’s lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce “ sustained antidepressant effects” in individuals living with severe depression.

Clinical Trials 52

Clinical Trials Research and Development Therapy Microdosing 52

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

DECEMBER 5, 2021

Funders are endorsing MAPS’ mission and pursuit of mass mental health backed by 35 years of innovative leadership, governance, programs, and strategies. Getting MAPS out ahead of the industry will create a commercial and cultural bar that puts patient access first.”.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

AUGUST 14, 2021

The deal signed in March had sought to progress an over-the-counter medicine with the TGA using Emyria’s EMD-003 program and Cann’s Gelpell technology. Cann Group (CAN) and Emyria (EMD) mutually agree to drop a deal for the proposed registration of a Schedule 3 cannabidiol (CBD) product. Shares in Cann Group were up 3.33

CBD 105

CBD Clinical Trials Programs Food 105

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

NORML

JANUARY 4, 2019

Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution. Legislation is pending, HB 350, to expand medical cannabis access. NH resident? GA resident?

Legislation 125

Legislation Clinical Trials Research and Development Access 125

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. The millions of people afflicted with PTSD may soon have access to MDMA therapy, and we believe the millions suffering from TBI may experience similar relief in the future.”.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

JANUARY 31, 2022

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Earlier this month, Health Canada added certain psychedelic compounds to the SAP that were previously available only through clinical trials. investment community.”

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

OCTOBER 2, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. European Regulatory Lead Executive Summary.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

MAY 29, 2022

Businesses have been recently receiving approval from Health Canada to farm psychedelic mushrooms, make psilocybin and sell the compound to drug-makers, or to doctors to give to patients. The psilocybin mushrooms are headed to clinical trials, drug companies and medical facilities. “I’m

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Cannabis Law Report

SEPTEMBER 12, 2022

The Company is working to supply various upcoming phase 1 & 2 clinical trials to build out the required human safety data in healthy Canadians, and eventually patients suffering from depression, anxiety, and PTSD. To access a complete photo gallery of this historic grow, please click here. Penis Envy. Blue Pulaski.

History 52

History Clinical Trials Legalization Research and Development 52

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

Veriheal

APRIL 11, 2022

He also emphasized the fact that medical cannabis programs are now legal in 37 states, as well as four out of five inhabited U.S. You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. territories. This means that U.S. Drug Enforcement Agency (DEA). federal law.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

MAY 10, 2022

The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions. The authors note, however, that the data doesn’t include patient outcomes.

Medicine 52

Medicine Clinical Trials Sleep Data 52

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. At the state level, patients in Ohio and Oklahoma now have access to medical cannabis, as sales began in both states this week. Additionally, a bipartisan coalition of U.S.

Legislation 164

Legislation Decriminalization Access Therapy 164

The Cannigma

AUGUST 26, 2021

Australia has a legal medical marijuana program, and while recreational cannabis remains illegal on the federal level, the enforcement of cannabis laws and the penalties handed out can differ widely from one territory to another. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Veriheal

AUGUST 31, 2020

Program between St. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. She is entering the 8-year Dual Admit B.S./M.D. Bonaventure University and George Washington University School of Medicine. .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA).

DEA 52

DEA Clinical Trials Policy Research and Development 52

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. Epidiolex contains less than 0.1

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

MARCH 29, 2022

Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA. Dawn remains a faculty member at Penn directing the QA course of study for the ITMAT Masters program.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. Position Requirements. FSA/Dep Care.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

SEPTEMBER 1, 2021

The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. After Approval, It’s Off to Treatment Clinics.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

JANUARY 13, 2020

We are proud of the positive impact this medicine has already had on thousands of patients and believe that this past year provides a compelling foundation for continued success in 2020,” said Justin Gover, GW’s Chief Executive Officer. Commence clinical program to expand future label to include spasticity associated with Spinal Cord Injury.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JANUARY 19, 2022

GMP psilocybin previously manufactured by Psygen personnel in collaboration with a licensed dealer using Psygen’s methods has already been used in clinical trials for development of therapeutic products. “A primary application for psychedelics is to support psychotherapy for treatment of mental health conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Clinical Trials and Human Subject Protections. Here are the top five considerations: 1.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 105

Law Therapy Clinical Trials Research and Development 105